factory supply 99% Gemcitabine Hydrochloride powder

factory supply 99% Gemcitabine Hydrochloride powder

Min.Order / FOB Price:Get Latest Price

1 Metric Ton	FOB Price:USD 20.0000 -50.0000

1 Metric Ton

FOB Price:USD 20.0000 -50.0000

Min.Order :1 Metric Ton
Purity: 99% up
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Gemcitabine Hydrochloride factory price High purity 99%

Quick Details

Appearance:White powder
Application:Suitable for the treatment of inoperable advanced
PackAge:1kg/bag ;5kg/drum:25KG/drum
ProductionCapacity:20|Metric Ton|Day
Storage:in low tempreture
Transportation:in low tempreture

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin

Details:

Product Information

Product Name	Gemcitabine hydrochloride
Synonyms	2',2'-difluorodeoxycytidinemonohydrochloride;2'-deoxy-2',2'-difluorocytidinemonohydrochloride;2'-deoxy-2',2'-difluoro-cytidinmonohydrochloride;gemzar;ly188011;ly188011hydrochloride;2',2'-DIFLUORO-2'-DEOXYCYTIDINE;2'-DEOXY-2',2'-DIFLUOROCYTIDINE
CAS	122111-03-9
MF	C9H12ClF2N3O4
MW	299.66
EINECS	601-823-3
Melting point	>250°C dec.
Density	1.137±0.06 g/cm3

Usage

Gemcitabine hydrochloride is a synthetic novel difluoro nucleoside drug that is anti-metabolic and antineoplastic. It is researched and developed by the Eli Lilly and Company and approved to be listed in South Africa, Sweden, the Netherlands, Australia and other countries in 1995. The United States Food and Drug Administration ( referred FDA) approved it as the first-line therapy for the clinical treatment of non-small cell lung cancer and pancreatic cancer.

Suitable for the treatment of inoperable advanced or metastatic pancreatic cancer and the treatment of locally advanced or metastatic non-small cell lung cancer, and the treatment for mid-term and advanced non-small cell lung cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.